drugset / Trial / NCT02772614

Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites

NCT02772614

Phase 1 Completed 4 enrolled Bial - Portela C S.A.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is: To determine the rate and routes of excretion of BIA 3-202 and the mass balance in urine and faeces To determine the kinetics of total radioactivity in blood To determine the kinetics of total radioactivity in plasma To determine the kinetics of BIA 3-202 and its metabolites in plasma

Timeline

Start
2006-01
Primary completion
2006-02
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Nebicapone Small molecule 200 mg Oral

Indications